← Leaderboards
Charles L Sawyers
Sloan-Kettering Inst Can Research
$34,701,646
Attributed
$34,701,646
Total exposure
24
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$46,219,980 · 26
By mechanism
P01$11,930,844 · 8
R01$9,510,162 · 4
U54$9,245,272 · 3
U01$7,985,164 · 1
P50$3,340,907 · 7
R25$2,175,113 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Megan Elizabeth Kelley$80,702
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateTumorAndrogen ReceptorProstateGene ExpressionPathway InteractionsBaseResistanceOrganoidsMutationCellsGenesMolecularGenomicsProgramsReceptor SignalingPlayInhibitor/AntagonistMalignant NeoplasmsResponsePhenotypeBiological MarkersDrug TargetingClinical Research
Grant awards (111)
Leveraging Observational (Real World) Data to Advance Precision Oncology$2,357,014
P01 · FY2025 · CA · contact PI
Project 1: Investigation of immune and stromal factors that promote prostate adenocarcinoma progression and castration response$487,709
P01 · FY2025 · CA · contact PI
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence$471,586
R01 · FY2025 · CA · contact PI
Administrative Core$220,792
P01 · FY2025 · CA · contact PI
Project 3: Therapeutic Targeting of Lineage Plasticity in Castration-Resistant Prostate Cancer$212,658
P50 · FY2025 · CA · contact PI
Leveraging Observational (Real World) Data to Advance Precision Oncology$2,372,456
P01 · FY2024 · CA · contact PI
Project 1: Investigation of immune and stromal factors that promote prostate adenocarcinoma progression and castration response$482,274
P01 · FY2024 · CA · contact PI
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence$448,006
R01 · FY2024 · CA · contact PI
Functional Evaluation and Interpretation of DNA Damage Repair Variants in Prostate Cancer$409,164
P01 · FY2024 · CA · contact PI
Project 3: Therapeutic Targeting of Lineage Plasticity in Castration-Resistant Prostate Cancer$275,993
P50 · FY2024 · CA · contact PI
Administrative Core$193,156
P01 · FY2024 · CA · contact PI
Project 1: Investigation of immune and stromal factors that promote prostate adenocarcinoma progression and castration response$493,245
P01 · FY2023 · CA · contact PI
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence$462,155
R01 · FY2023 · CA · contact PI
Functional Evaluation and Interpretation of DNA Damage Repair Variants in Prostate Cancer$419,377
P01 · FY2023 · CA · contact PI
Project 3: Therapeutic Targeting of Lineage Plasticity in Castration-Resistant Prostate Cancer$372,414
P50 · FY2023 · CA · contact PI
Molecular Biology in Clinical Oncology Workshop$70,000
R25 · FY2023 · CA · contact PI
Project 1: Investigation of immune and stromal factors that promote prostate adenocarcinoma progression and castration response$695,029
P01 · FY2022 · CA · contact PI
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence$462,155
R01 · FY2022 · CA · contact PI
Functional Evaluation and Interpretation of DNA Damage Repair Variants in Prostate Cancer$419,377
P01 · FY2022 · CA · contact PI
Understanding Resistance to Next Generation Antiandrogens$396,018
R01 · FY2022 · CA · contact PI
Project 3: Therapeutic Targeting of Lineage Plasticity in Castration-Resistant Prostate Cancer$381,380
P50 · FY2022 · CA · contact PI
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity Center$1,323,213
U54 · FY2021 · CA · contact PI
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence$471,586
R01 · FY2021 · CA · contact PI
Functional Evaluation and Interpretation of DNA Damage Repair Variants in Prostate Cancer$426,186
P01 · FY2021 · CA · contact PI
Understanding Resistance to Next Generation Antiandrogens$404,100
R01 · FY2021 · CA · contact PI
Project 1: Resistance caused by AR pathway reactivation$330,155
U54 · FY2021 · CA · contact PI
Molecular Biology in Clinical Oncology Workshop$249,978
R25 · FY2021 · CA · contact PI
Research Project 3: Heterogeneity in metastatic CRPC and the role of TP53 mutation as a molecular determinant$123,344
P50 · FY2021 · CA · contact PI
Administative Core$61,810
U54 · FY2021 · CA · contact PI
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity Center$1,416,545
U54 · FY2020 · CA · contact PI
Understanding Resistance to Next Generation Antiandrogens$404,100
R01 · FY2020 · CA · contact PI
Project 1: Resistance caused by AR pathway reactivation$352,577
U54 · FY2020 · CA · contact PI
Translational Research in Oncology Training Program$312,047
T32 · FY2020 · CA · contact PI
Research Project 3: Heterogeneity in metastatic CRPC and the role of TP53 mutation as a molecular determinant$208,235
P50 · FY2020 · CA · contact PI
Research Project 4:Investigating and targeting the glucocorticoid receptor (GR) in enzalutamide- and abiraterone-resistant prostate cancer$177,881
P50 · FY2020 · CA · contact PI
Administative Core$66,007
U54 · FY2020 · CA · contact PI
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity Center$1,323,213
U54 · FY2019 · CA · contact PI
Functional Evaluation and Interpretation of DNA Damage Repair Variants in Prostate Cancer$465,986
P01 · FY2019 · CA · contact PI
Defining the Role of ERG in Modulating the AR Cistrome and Antiandrogen Sensitivity$462,551
R01 · FY2019 · CA · contact PI
Understanding Resistance to Next Generation Antiandrogens$374,735
R01 · FY2019 · CA · contact PI
Project 1: Resistance caused by AR pathway reactivation$332,817
U54 · FY2019 · CA · contact PI
Molecular Biology in Clinical Oncology Workshop$249,978
R25 · FY2019 · CA · contact PI
Research Project 3: Heterogeneity in metastatic CRPC and the role of TP53 mutation as a molecular determinant$205,950
P50 · FY2019 · CA · contact PI
Research Project 4:Investigating and targeting the glucocorticoid receptor (GR) in enzalutamide- and abiraterone-resistant prostate cancer$177,648
P50 · FY2019 · CA · contact PI
Translational Research in Oncology Training Program$82,849
T32 · FY2019 · CA · contact PI
Administative Core$62,308
U54 · FY2019 · CA · contact PI
Defining the Role of ERG in Modulating the AR Cistrome and Antiandrogen Sensitivity$468,128
R01 · FY2018 · CA · contact PI
Understanding Resistance to Next Generation Antiandrogens$386,325
R01 · FY2018 · CA · contact PI
Molecular Biology in Clinical Oncology Workshop$249,978
R25 · FY2018 · CA · contact PI
Translational Research in Oncology Training Program$229,938
T32 · FY2018 · CA · contact PI
Research Project 3: Heterogeneity in metastatic CRPC and the role of TP53 mutation as a molecular determinant$218,023
P50 · FY2018 · CA · contact PI
Research Project 4:Investigating and targeting the glucocorticoid receptor (GR) in enzalutamide- and abiraterone-resistant prostate cancer$187,249
P50 · FY2018 · CA · contact PI
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity Center$139,999
U54 · FY2018 · CA · contact PI
Administative Core$139,999
U54 · FY2018 · CA · contact PI
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity Center$2,585,894
U54 · FY2017 · CA · contact PI
Project 1: Resistance caused by AR pathway reactivation$935,583
U54 · FY2017 · CA · contact PI
Defining the Role of ERG in Modulating the AR Cistrome and Antiandrogen Sensitivity$468,128
R01 · FY2017 · CA · contact PI
Molecular Biology in Clinical Oncology Workshop$249,978
R25 · FY2017 · CA · contact PI
Translational Research in Oncology Training Program$221,887
T32 · FY2017 · CA · contact PI
Research Project 3: Heterogeneity in metastatic CRPC and the role of TP53 mutation as a molecular determinant$216,797
P50 · FY2017 · CA · contact PI
Research Project 4:Investigating and targeting the glucocorticoid receptor (GR) in enzalutamide- and abiraterone-resistant prostate cancer$187,256
P50 · FY2017 · CA · contact PI
Administative Core$175,152
U54 · FY2017 · CA · contact PI
Defining the Role of ERG in Modulating the AR Cistrome and Antiandrogen Sensitivity$468,128
R01 · FY2016 · CA · contact PI
Understanding Resistance to Next Generation Antiandrogens$372,919
R01 · FY2016 · CA · contact PI
Molecular Biology in Clinical Oncology Workshop$249,978
R25 · FY2016 · CA · contact PI
Translational Research in Oncology Training Program$225,380
T32 · FY2016 · CA · contact PI
Research Project 3: Heterogeneity in metastatic CRPC and the role of TP53 mutation as a molecular determinant$215,465
P50 · FY2016 · CA · contact PI
Research Project 4:Investigating and targeting the glucocorticoid receptor (GR) in enzalutamide- and abiraterone-resistant prostate cancer$180,614
P50 · FY2016 · CA · contact PI
Defining the Role of ERG in Modulating the AR Cistrome and Antiandrogen Sensitivity$487,103
R01 · FY2015 · CA · contact PI
Understanding Resistance to Next Generation Antiandrogens$372,919
R01 · FY2015 · CA · contact PI
Translational Research in Oncology Training Program$178,334
T32 · FY2015 · CA · contact PI
Understanding Resistance to Next Generation Antiandrogens$361,732
R01 · FY2014 · CA · contact PI
Translational Research in Oncology Training Program$232,281
T32 · FY2014 · CA · contact PI
Understanding Resistance to Next Generation Antiandrogens$350,544
R01 · FY2013 · CA · contact PI
Translational Research in Oncology Training Program$208,412
T32 · FY2013 · CA · contact PI
Understanding Resistance to Next Generation Antiandrogens$372,919
R01 · FY2012 · CA · contact PI
Translational Research in Oncology Training Program$217,056
T32 · FY2012 · CA · contact PI
AKT-independent Pathways of Phosphoinositide 3-kinase dependent transformation$420,525
P01 · FY2011 · CA · contact PI
Translational Research in Oncology Training Program$111,062
T32 · FY2011 · CA · contact PI
AKT-independent Pathways of Phosphoinositide 3-kinase dependent transformation$435,028
P01 · FY2010 · CA · contact PI
AKT-independent Pathways of Phosphoinositide 3-kinase dependent transformation$428,015
P01 · FY2009 · CA · contact PI
Mouse Models for Human Prostate Cancer$878,546
U01 · FY2008 · CA · contact PI
AKT-independent Pathways of Phosphoinositide 3-kinase dependent transformation$418,107
P01 · FY2008 · CA · contact PI
Mouse Models for Human Prostate Cancer$869,845
U01 · FY2007 · CA · contact PI
AKT-independent Pathways of Phosphoinositide 3-kinase dependent transformation$424,430
P01 · FY2007 · CA · contact PI
Molecular Biology in Clinical Oncology Workshop$285,649
R25 · FY2007 · CA · contact PI
Mouse Models for Human Prostate Cancer$869,732
U01 · FY2006 · CA · contact PI
Molecular Biology in Clinical Oncology Workshop$285,610
R25 · FY2006 · CA · contact PI
Mouse Models for Human Prostate Cancer$155,555
U01 · FY2006 · CA · contact PI
Mouse Models for Human Prostate Cancer$863,622
U01 · FY2005 · CA
Molecular Biology in Clinical Oncology Workshop$283,964
R25 · FY2005 · CA
Mouse Models for Human Prostate Cancer$151,024
U01 · FY2005 · CA
PHASE I TRIAL OF 17-N-ALLYLAMINO-17-DEMETHOXY GELDANAMYCIN (17-AAG, NSC #330$3,176
M01 · FY2005 · RR
Mouse Models for Human Prostate Cancer$850,000
U01 · FY2004 · CA
Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330...$10,096
M01 · FY2004 · RR
MOUSE MODELS FOR HUMAN PROSTATE CANCER$1,144,549
U01 · FY2003 · CA
MOUSE MODELS FOR HUMAN PROSTATE CANCER$732,995
U01 · FY2002 · CA
REGULATION OF THE PTEN TUMOR SUPPRESSOR GENE IN PROSTATE CANCER$181,487
P01 · FY2002 · CA
MOUSE MODELS FOR HUMAN PROSTATE CANCER$64,083
U01 · FY2002 · CA
Targeted Therapy of PTEN Null Prostate Cancer$0
P50 · FY2002 · CA
Imaging prostate cancer bone metastasis$0
P50 · FY2002 · CA
Imaging prostate cancer bone metastasis$0
P50 · FY2002 · CA
MOUSE MODELS FOR HUMAN PROSTATE CANCER$712,536
U01 · FY2001 · CA
REGULATION OF THE PTEN GENE IN PROSTATE CANCER$272,169
R01 · FY2001 · CA
STEM CELL GENES IN PROSTATE GROWTH AND DIFFERENTIATION$253,354
R01 · FY2001 · DK
Imaging prostate cancer bone metastasis$0
P50 · FY2001 · CA
MOUSE MODELS FOR HUMAN PROSTATE CANCER$692,677
U01 · FY2000 · CA
REGULATION OF THE PTEN GENE IN PROSTATE CANCER$272,169
R01 · FY2000 · CA
STEM CELL GENES IN PROSTATE GROWTH AND DIFFERENTIATION$246,633
R01 · FY2000 · DK
ROLE OF C-ABLE NUCLEAR TYROSINE KINASE IN NORMAL AND MALIGNANT CELL GROWTH$181,487
P01 · FY2000 · CA
Imaging prostate cancer bone metastasis$0
P50 · FY2000 · CA